Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

•Stereotactic Body Radiotherapy Combined with Camrelizumab and Apatinib As Conversion Therapy Versus Camrelizumab Combined with Apatinib As First-Line Therapy for Unresectable Hepatocellular Carcinoma: a Prospective, Multicenter, Open-label, Randomized Controlled Clinical Trial.

NCT06739317 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT06739317
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06739317 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
•Stereotactic Body Radiotherapy Combined with Camrelizumab and Apatinib As Conversion Therapy Versus Camrelizumab Combined with Apatinib As First-Line Therapy for Unresectable Hepatocellular Carcinoma: a Prospective, Multicenter, Open-label, Randomized Controlled Clinical Trial.
Lead sponsor
Sun Yat-sen University
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
January 1, 2025
Completion date
June 30, 2031
Enrollment
398 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable hepatocellular carcinoma (hcc)